Arshneel S. Kochar

Cleveland Clinic Academic Setting

Author of 6 ePosters

 eCatalog Module
Heart Failure -> Cardiac Resynchronization Therapy: -> Indications D-AB13 - Beyond ICM and NICM: CRT in Emerging HF Populations (ID 54) Abstract

D-AB13-04 - Impact Of Cardiac Resynchronization Therapy On Survival In Patients With Transthyretin Cardiac Amyloidosis (ID 1432)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.
Cardiovascular Implantable Electronic Devices -> Tachycardia Devices: -> Indications D-AB21 - Real World Outcomes of Patients with an ICD (ID 7) Abstract

D-AB21-06 - Impact Of Primary Prevention Implantable Cardioverter-defibrillators On Survival In Patients With Transthyretin Cardiac Amyloidosis (ID 1451)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.
Clinical Electrophysiology -> Atrial Fibrillation & Atrial Flutter: -> Pharmacology (Antiarrhythmic drugs and anticoagulants) D-AB27 - Arrhythmias, infiltration and hypertrophy (ID 27) Abstract

D-AB27-02 - Rates Of Bleeding Requiring Anticoagulation Cessation In Patients With Transthyretin Cardiac Amyloidosis And Atrial Fibrillation (ID 1465)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.
Clinical Electrophysiology -> Atrial Fibrillation & Atrial Flutter: -> Pharmacology (Antiarrhythmic drugs and anticoagulants) D-BT01 - Cardiac Electrophysiology Society (CES): Lunch and Young Investigator Award Poster Session (ID 41) Special Session

D-BT01-30 - Rates Of Bleeding Requiring Anticoagulation Cessation In Patients With Transthyretin Cardiac Amyloidosis And Atrial Fibrillation (ID 864)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.
Heart Failure -> Cardiac Resynchronization Therapy: -> Indications D-BT01 - Cardiac Electrophysiology Society (CES): Lunch and Young Investigator Award Poster Session (ID 41) Special Session

D-BT01-32 - Impact Of Cardiac Resynchronization Therapy On Survival In Patients With Transthyretin Cardiac Amyloidosis (ID 866)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.
Catheter Ablation -> Atrial Fibrillation & Atrial Flutter: -> Clinical Trials / Outcomes D-PO03 - Poster Session III (ID 48) Poster

D-PO03-195 - Impact Of Risk Factor Modification On Arrhythmia Recurrence Rates Following Atrial Fibrillation Ablation In Nonalcoholic Fatty Liver Disease (ID 1151)

Authors
Disclosure
 E. Donnellan: Nothing relevant to disclose.